KR20180084335A - 적색형광단백질을 발현하는 유전자 및 틴 에틸 에티오푸르푸린을 이용한 광역학 치료용 조성물 및 이를 이용한 광역학 치료방법 - Google Patents

적색형광단백질을 발현하는 유전자 및 틴 에틸 에티오푸르푸린을 이용한 광역학 치료용 조성물 및 이를 이용한 광역학 치료방법 Download PDF

Info

Publication number
KR20180084335A
KR20180084335A KR1020170007301A KR20170007301A KR20180084335A KR 20180084335 A KR20180084335 A KR 20180084335A KR 1020170007301 A KR1020170007301 A KR 1020170007301A KR 20170007301 A KR20170007301 A KR 20170007301A KR 20180084335 A KR20180084335 A KR 20180084335A
Authority
KR
South Korea
Prior art keywords
photodynamic therapy
fluorescent protein
red fluorescent
tin ethyl
ethyl etiopurpurin
Prior art date
Application number
KR1020170007301A
Other languages
English (en)
Other versions
KR101911725B1 (ko
Inventor
문경수
Original Assignee
주식회사 코어파마
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 코어파마 filed Critical 주식회사 코어파마
Priority to KR1020170007301A priority Critical patent/KR101911725B1/ko
Priority to PCT/KR2018/000759 priority patent/WO2018131989A1/ko
Priority to JP2019559250A priority patent/JP6940185B2/ja
Priority to CN201880007163.9A priority patent/CN110198741B/zh
Priority to EP18739276.6A priority patent/EP3572094A4/en
Priority to US16/478,175 priority patent/US20190365927A1/en
Publication of KR20180084335A publication Critical patent/KR20180084335A/ko
Application granted granted Critical
Publication of KR101911725B1 publication Critical patent/KR101911725B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0023—Agression treatment or altering
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3681—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation
    • A61M1/3683—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation using photoactive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/067—Radiation therapy using light using laser light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/063—Radiation therapy using light comprising light transmitting means, e.g. optical fibres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light
    • A61N2005/0663—Coloured light

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

본 발명은 적색형광단백질을 발현하는 유전자 및 틴 에틸 에티오푸르푸린을 이용한 광역학 치료용 조성물 및 이를 이용한 광역학 치료방법에 관한 것으로, 구체적으로 적색형광단백질이 도입된 암세포에 광감작제로서 틴 에틸 에티오푸르푸린(tin ethyl etiopurpurin)을 처리한 후 황색광을 조사하여 정상세포에는 영향을 미치지 않고 적색형광단백질이 도입된 암세포만을 선택적으로 사멸시킬 수 있는 광역학 치료용 조성물 및 이를 이용한 광역학 치료방법을 제공한다.
KR1020170007301A 2017-01-16 2017-01-16 적색형광단백질을 발현하는 유전자 및 틴 에틸 에티오푸르푸린을 이용한 광역학 치료용 조성물 및 이를 이용한 광역학 치료방법 KR101911725B1 (ko)

Priority Applications (6)

Application Number Priority Date Filing Date Title
KR1020170007301A KR101911725B1 (ko) 2017-01-16 2017-01-16 적색형광단백질을 발현하는 유전자 및 틴 에틸 에티오푸르푸린을 이용한 광역학 치료용 조성물 및 이를 이용한 광역학 치료방법
PCT/KR2018/000759 WO2018131989A1 (ko) 2017-01-16 2018-01-16 형광단백질을 발현하는 유전자 및 광감작제를 이용한 광역학 치료용 조성물 및 이를 이용한 광역학 치료방법
JP2019559250A JP6940185B2 (ja) 2017-01-16 2018-01-16 蛍光タンパク質を発現する遺伝子及び光感作剤を用いた光力学治療用組成物及びこれを用いた光力学治療方法
CN201880007163.9A CN110198741B (zh) 2017-01-16 2018-01-16 利用表达荧光蛋白的基因及光敏剂的光动力治疗用组合物及利用其的光动力治疗方法
EP18739276.6A EP3572094A4 (en) 2017-01-16 2018-01-16 COMPOSITION FOR PHOTODYNAMIC THERAPY USING A GENE EXPRESSING FLUORESCENCE PROTEIN AND A PHOTOSENSITIZER AND A PHOTODYNAMIC THERAPY PROCEDURE WITH IT
US16/478,175 US20190365927A1 (en) 2017-01-16 2018-01-16 Composition for photodynamic therapy using gene expressing fluorescent protein and photosensitizer, and photodynamic therapy method using same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020170007301A KR101911725B1 (ko) 2017-01-16 2017-01-16 적색형광단백질을 발현하는 유전자 및 틴 에틸 에티오푸르푸린을 이용한 광역학 치료용 조성물 및 이를 이용한 광역학 치료방법

Publications (2)

Publication Number Publication Date
KR20180084335A true KR20180084335A (ko) 2018-07-25
KR101911725B1 KR101911725B1 (ko) 2018-12-28

Family

ID=62839928

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020170007301A KR101911725B1 (ko) 2017-01-16 2017-01-16 적색형광단백질을 발현하는 유전자 및 틴 에틸 에티오푸르푸린을 이용한 광역학 치료용 조성물 및 이를 이용한 광역학 치료방법

Country Status (6)

Country Link
US (1) US20190365927A1 (ko)
EP (1) EP3572094A4 (ko)
JP (1) JP6940185B2 (ko)
KR (1) KR101911725B1 (ko)
CN (1) CN110198741B (ko)
WO (1) WO2018131989A1 (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2924861T3 (es) 2017-03-28 2022-10-11 Univ Keio Célula madre tisular humana y uso de la misma
CN111855541A (zh) * 2019-04-26 2020-10-30 朱德新 循环肿瘤细胞检测试剂、试剂盒和检测方法
WO2021192113A1 (ja) * 2020-03-25 2021-09-30 大塚メディカルデバイス株式会社 がんの処置方法およびそのためのシステム

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101035269B1 (ko) 2007-04-23 2011-05-26 한국과학기술연구원 고분자 유도체-광감작제 복합체를 이용한 새로운 광역학치료제
KR101288460B1 (ko) 2009-06-26 2013-07-26 주식회사 진코스 양자점-클로린 유도체의 접합체를 함유하는 광감작제 및 이를 포함하는 광역학 치료에 사용하기 위한 암 치료 및 진단용 조성물
KR101405403B1 (ko) 2010-01-20 2014-06-11 주식회사 진코스 클로린 유도체와 불포화 지방산의 접합체, 이를 함유하는 광감작제, 및 이를 포함하는 광역학 치료에 사용하기 위한 암 치료용 조성물
KR101419124B1 (ko) 2011-09-16 2014-07-11 가톨릭대학교 산학협력단 폴리에틸렌옥사이드-폴리프로필렌옥사이드 블록공중합체와 광감작제가 공유 결합된 광역학 치료용 복합체

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1346059B1 (en) * 2000-11-29 2012-05-23 PCI Biotech AS Photochemical internalization for delivery of molecules into the cytosol
GB0520436D0 (en) * 2005-10-07 2005-11-16 Photobiotics Ltd Biological materials and uses thereof
EP2189528A4 (en) * 2007-08-03 2010-09-22 Univ Hokkaido Nat Univ Corp FLUORESCENCE PROTEIN WITH DEEP BLUE COLOR
KR20140007976A (ko) * 2008-05-14 2014-01-20 노바다크 테크놀러지즈 인코포레이티드 신경 영상 진단용 바이러스 성분들과 결합된 형광 염료를 포함하는 조성물
ES2627026T3 (es) * 2011-09-05 2017-07-26 Hiroshi Maeda Sonda molecular fluorescente de tipo polímero
KR101323848B1 (ko) * 2012-05-18 2013-11-01 광주과학기술원 소수성 형광입자 및 광감작제-운반 폴리머좀 복합체
WO2014055960A1 (en) * 2012-10-05 2014-04-10 Genelux Corporation Energy absorbing-based diagnostic and therapeutic methods employing nucleic acid molecules encoding chromophore-producing enzymes
KR101668561B1 (ko) * 2015-07-13 2016-10-21 원광대학교산학협력단 녹색형광단백질을 발현하는 유전자 및 로즈 벵갈을 이용한 암 질환의 광역학 치료용 조성물 및 이를 이용한 광역학 치료방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101035269B1 (ko) 2007-04-23 2011-05-26 한국과학기술연구원 고분자 유도체-광감작제 복합체를 이용한 새로운 광역학치료제
KR101288460B1 (ko) 2009-06-26 2013-07-26 주식회사 진코스 양자점-클로린 유도체의 접합체를 함유하는 광감작제 및 이를 포함하는 광역학 치료에 사용하기 위한 암 치료 및 진단용 조성물
KR101405403B1 (ko) 2010-01-20 2014-06-11 주식회사 진코스 클로린 유도체와 불포화 지방산의 접합체, 이를 함유하는 광감작제, 및 이를 포함하는 광역학 치료에 사용하기 위한 암 치료용 조성물
KR101419124B1 (ko) 2011-09-16 2014-07-11 가톨릭대학교 산학협력단 폴리에틸렌옥사이드-폴리프로필렌옥사이드 블록공중합체와 광감작제가 공유 결합된 광역학 치료용 복합체

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Castano, A. P., et al. Mechanisms in photodynamic therapy: Part threePhotosensitizer pharmacokinetics, biodistribution, tumor localization and modes of tumor destruction. Photodiagnosis and Photodynamic Therapy 2(2), 91-106 (2005).
Castano, A. P., Mroz, P. & Hamblin, M. R. Photodynamic therapy and anti-tumour immunity. Nature Reviews Cancer 6, 535-545 (2006).
Liang-yan Xue et al., The Death of Human Cancer Cells Following Photodynamic Therapy: Apoptosis Competence is Necessary for Bcl-2 Protection but not for Induction of Autophagy Photochemistry and Photobiology 83(5), 1016-1023 (2007).
Wang, J. et al. Carbon nanodots featuring efficient FRET for two-photon photodynamic cancer therapy with a low fs laser power density. Biomaterials 35, 9372-9381 (2014).

Also Published As

Publication number Publication date
EP3572094A1 (en) 2019-11-27
CN110198741B (zh) 2022-02-08
KR101911725B1 (ko) 2018-12-28
EP3572094A4 (en) 2020-10-21
JP2020513212A (ja) 2020-05-07
US20190365927A1 (en) 2019-12-05
JP6940185B2 (ja) 2021-09-22
CN110198741A (zh) 2019-09-03
WO2018131989A1 (ko) 2018-07-19

Similar Documents

Publication Publication Date Title
MX2020005463A (es) Anticuerpos anti grupo de diferenciacion 47 (anti-cd47) y sus usos para tratar cancer.
EA201792191A1 (ru) Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли
EA201001621A1 (ru) Новые терапевтические средства и способы лечения слепоты
MX2021012285A (es) Compuestos de piperidina 3-sustituidos para inhibicion del protooncogen-b de linfoma de linea b de casitas (cbl-b) y uso de un inhibidor de cbl-b en combinacion con una vacuna contra el cancer y/o con un virus oncolitico.
AU2018372763A1 (en) Materials and methods for treatment of autosomal dominant Retinitis Pigmentosa
MX2018014256A (es) Metodos de terapia genica para enfermedades y condiciones relacionadas con la edad.
EA201890961A1 (ru) Комбинированная терапия для лечения злокачественных новообразований
EA201590085A1 (ru) Антитела анти-egfr и их применение
WO2018203083A3 (en) Calcium peroxides nanoparticles as adjuvant therapy
MX2020007060A (es) Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas.
MX2017013142A (es) Terapia combinada para tratar cáncer.
BR112018007656A2 (pt) terapia de combinação para tratamento de doenças malignas
WO2012086991A3 (ko) 광 치료장치 및 이의 제어방법
WO2019079201A3 (en) A photosensitive compound in a polymeric nanoparticle, and a method of using the same
EA201791535A1 (ru) Новое соединение 4'-тионуклеозида, а также способ его получения, его фармацевтическая композиция и применение
KR20180084335A (ko) 적색형광단백질을 발현하는 유전자 및 틴 에틸 에티오푸르푸린을 이용한 광역학 치료용 조성물 및 이를 이용한 광역학 치료방법
EP3492096A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF EYE DISEASES WITH CAS9 PROTEINS AND GUIDE RNA
MX2018015172A (es) Metodos para tratar cancer pancreatico.
AU2018271862A1 (en) Combination therapy
MX2023004156A (es) Terapia combinada para el tratamiento del cancer.
AU2018337076A1 (en) Method of treatment
WO2019112978A3 (en) Anti-dclk1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof
WO2018125800A3 (en) Metalloenzyme inhibitor compounds
EA202092540A1 (ru) Комбинации для лечения рака
MX2023006551A (es) Tratamiento de las convulsiones refractarias.

Legal Events

Date Code Title Description
A201 Request for examination
N231 Notification of change of applicant
E701 Decision to grant or registration of patent right